NCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
Clinical Trials
17 trialsNCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT02826486 2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2 Completed
NCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02697058 2024-07-25
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Servier
Phase 2 Completed
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT04727853 2024-07-10
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT02551991 2022-10-10
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Ipsen
Phase 2 Completed
NCT05086822 2021-10-21
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03446872 2021-09-28
Post Marketing Surveillance Study for ONIVYDE® in South Korea
Servier
Completed
NCT01770353 2019-11-27
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
Phase 1 Completed
NCT00364143 2019-07-05
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors
Yakult Honsha Co., LTD
Phase 1 Completed
NCT02884128 2016-08-30
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
PharmaEngine
Phase 1 Completed
NCT01494506 2016-06-17
NAPOLI-1
Merrimack Pharmaceuticals
Phase 3 Completed